SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · BioNTech filed a 6-K press release announcing upcoming data…

BioNTech SE · 6-K filed Aug 20, 2026 at 07:36 ET

At the news

NEUTRALIMPACT 4/10

6-K filed Aug 20, 2026 at 07:36 ET

BioNTech filed a 6-K press release announcing upcoming data presentations at the IASLC 2026 World Conference on Lung Cancer (WCLC), including first global data for the novel-novel combination of pumitamig plus elfetabart drozuntecan and updated overall survival data for gotistobart from the PRESERVE-003 Phase 3 trial. The filing is a routine pipeline update with no financial data, and the actual clinical results will not be disclosed until the conference in September 2026, limiting near-term trading impact.

  • BioNTech will present data at WCLC 2026 (Sept 12-15) from its lung cancer pipeline, including first data for pumitamig + elfetabart drozuntecan combination and updated OS for gotistobart.
  • The filing is a curtain-raiser press release with no clinical results disclosed; actual data will be presented at the conference.
  • BioNTech has 16 ongoing lung cancer trials, including five Phase 3 and two novel-novel combination trials.
  • No financial figures, guidance, or material agreements were included in this filing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access